0001246360-19-000765.txt : 20190225 0001246360-19-000765.hdr.sgml : 20190225 20190225174911 ACCESSION NUMBER: 0001246360-19-000765 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190221 FILED AS OF DATE: 20190225 DATE AS OF CHANGE: 20190225 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Swan Winifred L CENTRAL INDEX KEY: 0001341405 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51567 FILM NUMBER: 19630815 MAIL ADDRESS: STREET 1: NXSTAGE MEDICAL INC STREET 2: 439 SOUTH UNION STREET 5TH FLOOR CITY: LAWRENCE STATE: MA ZIP: 01843 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NxStage Medical, Inc. CENTRAL INDEX KEY: 0001333170 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 043454702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 350 MERRIMACK STREET CITY: LAWRENCE STATE: MA ZIP: 01843 BUSINESS PHONE: 978-687-4700 MAIL ADDRESS: STREET 1: 350 MERRIMACK STREET CITY: LAWRENCE STATE: MA ZIP: 01843 4 1 form.xml PRIMARY DOCUMENT X0306 4 2019-02-21 true 0001333170 NxStage Medical, Inc. NXTM 0001341405 Swan Winifred L 350 MERRIMACK STREET LAWRENCE MA 01843 false true false false SVP and General Counsel Common Stock 2019-02-21 4 D false 13077 30 D 0 D Stock Option (Right to Buy) 11.03 2019-02-21 4 D false 11542 0 D 2013-04-04 2023-03-03 Common Stock 11542 0 D Stock Option (Right to Buy) 14.66 2019-02-21 4 D false 49529 0 D 2014-04-10 2024-03-09 Common Stock 49529 0 D Stock Option (Right to Buy) 16.66 2019-02-21 4 D false 53315 0 D 2015-04-03 2025-03-02 Common Stock 53315 0 D Stock Option (Right to Buy) 15.58 2019-02-21 4 D false 71509 0 D 2016-04-09 2026-03-08 Common Stock 71509 0 D Stock Option (Right to Buy) 27.89 2019-02-21 4 D false 39884 0 D 2017-04-09 2027-03-08 Common Stock 39884 0 D Restricted Stock Unit 0 2019-02-21 4 D false 9314 0 D 2018-03-09 2020-03-09 Common Stock 13971 0 D Disposed of under Merger Agreement with Fresenius Medical Care Holdings, Inc. in which all outstanding shares of Issuer's Common Stock were converted into the right to receive $30 per share in cash. This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. These performance shares were canceled in the Merger in exchange for an amount in cash equal to the product of the total number of performance shares multiplied by the Merger Consideration of $30 per share. /s/ Aras Lapinskas, attorney-in-fact for Winifred Swan 2019-02-25